Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

United Therapeutics Corporation - Common Stock (NQ:UTHR)

571.38 +29.49 (+5.44%)

Delayed Quote Updated: 4:00 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	1,691,478
Open	557.53
Bid (Size)	569.00 (40)
Ask (Size)	573.00 (40)
Prev. Close	541.89
Today's Range	556.76 - 585.79
52wk Range	409.07 - 609.35
Shares Outstanding	44,891,523
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Stocks making big moves yesterday: United Therapeutics, Moderna, Jabil, Concentrix, and FactSet

Today 9:00 EDT

Check out the companies making headlines yesterday: United Therapeutics (NASDAQ:UTHR): Biotechnology company United Therapeutics (NASDAQ:UTHR) rose by 13.6% ...

Via StockStory

1 Mid-Cap Stock to Research Further and 2 That Underwhelm

Today 0:38 EDT

Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...

Via StockStory

Performance

YTD	+15.0%	+15.0%
1 Month	+12.0%	+12.0%
3 Month	+4.4%	+4.4%
6 Month	+0.2%	+0.2%
1 Year	+36.3%	+36.3%

More News

United Therapeutics Corporation Prevails in Patent Litigation Against Liquidia

September 30, 2026

From United Therapeutics

Via Business Wire

Why Is United Therapeutics (UTHR) Stock Rocketing Higher Today

September 30, 2026

Via StockStory

United Therapeutics (NASDAQ:UTHR): A Growth-at-a-Reasonable-Price Candidate ↗

September 24, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR) Screens as a High-Quality, Debt-Free Stock ↗

September 21, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model ↗

September 03, 2026

Via Chartmill

United Therapeutics Maps 14 Launches, Fibrosis Growth and Xenokidney Ambitions ↗

September 25, 2026

Via MarketBeat

Why United Therapeutics (UTHR) Shares Are Falling Today

September 24, 2026

Via StockStory

1 Cash-Heavy Stock to Target This Week and 2 We Question

September 11, 2026

Via StockStory

Therapeutics Stocks Q2 Teardown: United Therapeutics (NASDAQ:UTHR) Vs The Rest

September 08, 2026

Via StockStory

United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns ↗

August 20, 2026

Via Chartmill

United Therapeutics (NASDAQ:UTHR): A Peter Lynch-Style GARP Play ↗

August 13, 2026

Via Chartmill

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

September 08, 2026

From United Therapeutics Corporation

Via Business Wire

3 Profitable Stocks We’re Skeptical Of

September 03, 2026

Via StockStory

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

September 02, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Participation at Upcoming Investor Conferences

September 01, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Presents Data at The European Society of Cardiology Congress 2026 and The European Respiratory Society International Congress 2026

August 28, 2026

From United Therapeutics Corporation

Via Business Wire

3 Cash-Producing Stocks We Keep Off Our Radar

August 26, 2026

Via StockStory

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

August 24, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics Corporation Announces Full Enrollment of the TETON-PPF Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

August 17, 2026

From United Therapeutics Corporation

Via Business Wire

United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Via The Motley Fool

United Therapeutics’s Q2 Earnings Call: Our Top 5 Analyst Questions

August 12, 2026

Via StockStory

UTHR Q2 2026 Deep Dive: Product Pipeline Developments Offset Competitive Pressures

August 06, 2026

Via StockStory

United Therapeutics Q2 Earnings Call Highlights ↗

August 05, 2026

Via MarketBeat

Frequently Asked Questions

Is United Therapeutics Corporation - Common Stock publicly traded?

Yes, United Therapeutics Corporation - Common Stock is publicly traded.

What exchange does United Therapeutics Corporation - Common Stock trade on?

United Therapeutics Corporation - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for United Therapeutics Corporation - Common Stock?

The ticker symbol for United Therapeutics Corporation - Common Stock is UTHR on the Nasdaq Stock Market

What is the current price of United Therapeutics Corporation - Common Stock?

The current price of United Therapeutics Corporation - Common Stock is 571.38

When was United Therapeutics Corporation - Common Stock last traded?

The last trade of United Therapeutics Corporation - Common Stock was at 10/01/26 04:00 PM ET

What is the market capitalization of United Therapeutics Corporation - Common Stock?

The market capitalization of United Therapeutics Corporation - Common Stock is 25.65B

How many shares of United Therapeutics Corporation - Common Stock are outstanding?

United Therapeutics Corporation - Common Stock has 26B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.